Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1835

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease With High Proteinuria

Interventions

DRUG: Zibotentan/Dapagliflozin
DRUG: Dapagliflozin

Sponsor

AstraZeneca